190 related articles for article (PubMed ID: 35934771)
21. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
[TBL] [Abstract][Full Text] [Related]
22. Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer.
Callender T; Emberton M; Morris S; Pharoah PDP; Pashayan N
JAMA Netw Open; 2021 Mar; 4(3):e2037657. PubMed ID: 33704474
[TBL] [Abstract][Full Text] [Related]
23. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.
Zubek VB; Konski A
Mol Diagn Ther; 2009; 13(1):31-47. PubMed ID: 19351214
[TBL] [Abstract][Full Text] [Related]
25. Optimization of PSA screening policies: a comparison of the patient and societal perspectives.
Zhang J; Denton BT; Balasubramanian H; Shah ND; Inman BA
Med Decis Making; 2012; 32(2):337-49. PubMed ID: 21933990
[TBL] [Abstract][Full Text] [Related]
26. The prostate: decreasing cost-effectiveness of biopsy with advancing age.
Gottlieb RH; Mooney C; Mushlin AI; Rubens DJ; Fultz PJ
Invest Radiol; 1996 Feb; 31(2):84-90. PubMed ID: 8750443
[TBL] [Abstract][Full Text] [Related]
27. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
[TBL] [Abstract][Full Text] [Related]
28. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
[TBL] [Abstract][Full Text] [Related]
30. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
Littrup PJ; Kane RA; Mettlin CJ; Murphy GP; Lee F; Toi A; Badalament R; Babaian R
Cancer; 1994 Dec; 74(12):3146-58. PubMed ID: 7526969
[TBL] [Abstract][Full Text] [Related]
31. Economic evaluation of prostate cancer risk assessment methods: A cost-effectiveness analysis using population data.
Mohammadi T; Guh DP; Tam ACT; Pataky RE; Black PC; So A; Lynd LD; Zhang W; Conklin AI
Cancer Med; 2023 Oct; 12(19):20106-20118. PubMed ID: 37740609
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of diagnostic localization following biochemical prostate cancer recurrence.
Barocas DA; Bensink ME; Berry K; Musa Z; Bodnar C; Dann R; Ramsey SD
Int J Technol Assess Health Care; 2014 Oct; 30(4):345-53. PubMed ID: 25399914
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness Analysis of Prostate Cancer Screening in Brazil.
Oliveira RAR; Mourão TC; Santana TBM; Favaretto RL; Zequi SC; Guimarães GC
Value Health Reg Issues; 2021 Dec; 26():89-97. PubMed ID: 34146776
[TBL] [Abstract][Full Text] [Related]
35. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.
Sathianathen NJ; Kuntz KM; Alarid-Escudero F; Lawrentschuk NL; Bolton DM; Murphy DG; Weight CJ; Konety BR
J Urol; 2018 Dec; 200(6):1215-1220. PubMed ID: 29906434
[TBL] [Abstract][Full Text] [Related]
36. Prostate Cancer Screening Using Prostate-Specific Antigen Tests in a High-Risk Population in China: A Cost-Utility Analysis.
Qin X; Ye D; Gu C; Huang Y; Gu W; Dai B; Zhang H; Zhu Y; Yang H; Qu S
Curr Ther Res Clin Exp; 2021; 95():100653. PubMed ID: 34917218
[TBL] [Abstract][Full Text] [Related]
37. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis.
Martin AJ; Lord SJ; Verry HE; Stockler MR; Emery JD
Med J Aust; 2013 Jun; 198(10):546-50. PubMed ID: 23725269
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness Comparison of Imaging-Guided Prostate Biopsy Techniques: Systematic Transrectal Ultrasound, Direct In-Bore MRI, and Image Fusion.
Venderink W; Govers TM; de Rooij M; Fütterer JJ; Sedelaar JPM
AJR Am J Roentgenol; 2017 May; 208(5):1058-1063. PubMed ID: 28225639
[TBL] [Abstract][Full Text] [Related]
40. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
